First Patient dosed in Ph 1/2a Clinical Trial of BPT567 in patients with solid tumors October 22, 2024
35 sites active and enrolling in pivotal Ph 3 study of Bria-IMT™ combination with immune check point inhibitor in metastatic breast cancer (MBC) October 22, 2024
First Patient Dosed in Ph 1/2 Trial of PFL-241/STX-241 in Locally Advanced or Metastatic NSCLC patients October 15, 2024
Ph 3 SunRISe-2 trial in MIBC patients discontinued for not showing superiority versus chemoradiation October 15, 2024
First patient enrolled in Ph 1/2a clinical trial for Lenti-HPV07 against oropharyngeal and cervical cancers October 15, 2024
BDTX-1535 program to be advanced into pivotal development based on robust Ph 2 clinical data from EGFRm NSCLC patients October 15, 2024
First Patient Dosed in Ph 2 Clinical Trial of Radspherin® in Ovarian Cancer Patients October 15, 2024
First Patient Dosed in Ph 3 Clinical Trial of UGN-103 in patients with Low-Grade Intermediate-Risk NMIBC October 8, 2024
First Patient Dosed in Ph 1b Trial, MELODY-1 of MB097 Precision Microbiome Co-Therapy in Advanced Melanoma October 8, 2024
Key Progress and Upcoming Studies for Pelareorep Breast and Pancreatic Cancer Treatments Announced in Preparation for FDA Accelerated Approval Path October 8, 2024
Enrollment completed in Ph 2 proof of concept 065-101 study of fadraciclib in patients with advanced solid tumors and lymphoma; ongoing in T-Cell Lymphoma cohort October 2, 2024
Enrollment discontinued in Ph 3 KarMMa-9 study of Abecma with lenalidomide maintenance in newly diagnosed multiple myeloma (NDMM) patients with suboptimal response after autoSCT October 2, 2024
Deltacel-01 Advanced Into Expansion Phase Following Safety Monitoring Committee’s Unanimous Recommendation September 24, 2024
TIL-based cNeT program to be discontinued and Ph 1/2a CHIRON and THETIS clinical trials to be closed September 24, 2024
Two Patients Now Exceeding 1 Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial September 22, 2024
